window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : September 5, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Precision Medicine

  • Central Nervous System,Digital & Data,Drug Delivery & Formulation,Drug Discovery & Development,Therapeutic Areas

    Bonito Biosciences partners with DaltonTx on AI-driven RNA delivery research

    Bonito Biosciences has entered a collaboration with DaltonTx to develop [...]

    June 6, 2026
  • Clinical & Regulatory,Drug Discovery & Development

    Japan pushes AI clinical trials agenda as global pharma leaders gather in Tokyo

    Japan’s push to modernise clinical research through artificial intelligence and [...]

    May 7, 2026
  • Uncategorised

    Longitude Prize on ALS awards £2m to AI drug discovery teams

    The Longitude Prize on ALS has awarded £2 million to [...]

    May 7, 2026
  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development

    Myomaker Bio launches lab-grown human muscle platform for preclinical drug testing

    Myomaker Bio, a UK biotechnology company spun out from Loughborough [...]

    May 5, 2026
  • Clinical & Regulatory,Digital & Data,Drug Discovery & Development,Genomics and sequencing,Therapeutic Areas

    23andMe study links genetics to GLP-1 weight loss outcomes and side effects

    This Nature-published study from the 23andMe Research Institute identifies genetic [...]

    May 5, 2026
  • Central Nervous System,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics

    Alto Neuroscience completes Phase 2 enrollment for ALTO-101 in cognitive impairment associated with schizophrenia

    Alto Neuroscience has completed patient enrollment in its Phase 2 [...]

    May 5, 2026
  • Biotech & Pharma Business,Drug Discovery & Development,Opinion & Events,Therapeutic Areas

    UK national cancer plan aims to boost survival and cut inequalities in diagnosis and treatment

    The UK Government this World Cancer Day has published its [...]

    May 5, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    Nine-gene signature linked to lapatinib resistance in HER2-positive breast cancer

    Researchers at City St George’s, University of London have identified [...]

    May 5, 2026
  • Biotech & Pharma Business,Digital & Data,Drug Discovery & Development,Pharmaceuticals and therapeutics

    CytoReason unveils LINA, AI agent accelerated by NVIDIA for pharma R&D

    CytoReason has unveiled LINA, an AI agent designed to support [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Drug Discovery & Development,Genomics and sequencing,Therapeutic Areas

    PacBio HiFi adopted to study sudden unexplained death in childhood and advance precision therapies for rare diseases

    PacBio is supporting two research initiatives that use its HiFi [...]

    May 5, 2026
Previous234Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Polaryx advances Phase 2 trial of PLX-200 in four rare diseases
    Categories: Clinical & Regulatory, Drug Discovery & Development, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • Lumen Bioscience gets up to $7M to advance LMN-1001 into Phase 1
    Categories: Advanced Therapies, Clinical & Regulatory, Drug Discovery & Development, Pharmaceuticals and therapeutics, Research & Development
  • Brainomix to present five ILD studies on quantitative CT at ERS Congress
    Categories: Advanced Therapies, Clinical & Regulatory, Digital & Data, Research & Development, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top